日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis

膝骨关节炎或类风湿性关节炎患者血清软骨寡聚基质蛋白水平的昼夜变化

Andersson, M L E; Petersson, I F; Karlsson, K E; Jonsson, E N; Månsson, B; Heinegård, D; Saxne, T

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

一项针对瑞典接受依那西普治疗患者的全国性上市后队列研究结果显示,这些患者均来自瑞典。

Feltelius, N; Fored, C M; Blomqvist, P; Bertilsson, L; Geborek, P; Jacobsson, L T; Lindblad, S; Lysholm, J; Rantapää-Dahlqvist, S; Saxne, T; Klareskog, L

Prognostic laboratory markers of joint damage in rheumatoid arthritis

类风湿性关节炎关节损伤的预后实验室标志物

Lindqvist, E; Eberhardt, K; Bendtzen, K; Heinegård, D; Saxne, T

CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis

CNI-1493 是一种促炎细胞因子抑制剂,可延缓胶原诱导性关节炎大鼠的软骨破坏。

Larsson, E; Harris, H E; Palmblad, K; Månsson, B; Saxne, T; Klareskog, L

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

肿瘤坏死因子阻滞剂不会增加类风湿性关节炎患者的总体肿瘤风险,但可能与淋巴瘤风险增加有关。

Geborek, P; Bladström, A; Turesson, C; Gulfe, A; Petersson, I F; Saxne, T; Olsson, H; Jacobsson, L T H

Response criteria for rheumatoid arthritis in clinical practice: how useful are they?

类风湿性关节炎临床实践中的疗效评价标准:它们有多大用处?

Gülfe, A; Geborek, P; Saxne, T

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

类风湿性关节炎患者及接受肿瘤坏死因子拮抗剂治疗后罹患实体瘤的风险

Askling, J; Fored, C M; Brandt, L; Baecklund, E; Bertilsson, L; Feltelius, N; Cöster, L; Geborek, P; Jacobsson, L T; Lindblad, S; Lysholm, J; Rantapää-Dahlqvist, S; Saxne, T; Klareskog, L

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

类风湿性关节炎患者的造血系统恶性肿瘤:肿瘤坏死因子拮抗剂暴露后的淋巴瘤风险和特征

Askling, J; Fored, C M; Baecklund, E; Brandt, L; Backlin, C; Ekbom, A; Sundström, C; Bertilsson, L; Cöster, L; Geborek, P; Jacobsson, L T; Lindblad, S; Lysholm, J; Rantapää-Dahlqvist, S; Saxne, T; Klareskog, L; Feltelius, N

Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis

类风湿性关节炎患者关节内注射糖皮质激素治疗后,软骨和骨标志物的变化(有或无注射后休息)

Weitoft, T; Larsson, A; Saxne, T; Rönnblom, L

Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales

瑞典南部生物抗风湿药物使用情况的人群研究:与药品销售额的比较

Geborek, P; Nitelius, E; Noltorp, S; Petri, H; Jacobsson, L; Larsson, L; Saxne, T; Leden, I